Advertisement
Australia markets closed
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • AUD/USD

    0.6410
    -0.0015 (-0.24%)
     
  • OIL

    82.01
    -0.72 (-0.87%)
     
  • GOLD

    2,392.30
    -5.70 (-0.24%)
     
  • Bitcoin AUD

    102,015.96
    +4,236.13 (+4.33%)
     
  • CMC Crypto 200

    1,333.60
    +20.98 (+1.63%)
     
  • AUD/EUR

    0.6016
    -0.0015 (-0.24%)
     
  • AUD/NZD

    1.0892
    +0.0017 (+0.15%)
     
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     
  • FTSE

    7,830.59
    -46.46 (-0.59%)
     
  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     
  • DAX

    17,729.53
    -107.87 (-0.60%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Who Has Been Buying Phylogica Limited (ASX:PYC) Shares?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention that insider sales have been known to precede tough periods for a business. So before you buy or sell Phylogica Limited (ASX:PYC), you may well want to know whether insiders have been buying or selling.

What Is Insider Buying?

It is perfectly legal for company insiders, including board members, to buy and sell stock in a company. However, rules govern insider transactions, and certain disclosures are required.

We would never suggest that investors should base their decisions solely on what the directors of a company have been doing. But it is perfectly logical to keep tabs on what insiders are doing. As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

ADVERTISEMENT

View our latest analysis for Phylogica

The Last 12 Months Of Insider Transactions At Phylogica

insider Bernard Hockings made the biggest insider purchase in the last 12 months. That single transaction was for AU$1m worth of shares at a price of AU$0.03 each. Even though the purchase was made at a significantly lower price than the recent price (AU$0.056), we still think insider buying is a positive. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.

You can see a visual depiction of insider transactions (by individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

ASX:PYC Recent Insider Trading, October 11th 2019
ASX:PYC Recent Insider Trading, October 11th 2019

Phylogica is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership of Phylogica

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. Phylogica insiders own about AU$39m worth of shares. That equates to 31% of the company. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

So What Does This Data Suggest About Phylogica Insiders?

There haven't been any insider transactions in the last three months -- that doesn't mean much. However, our analysis of transactions over the last year is heartening. Insiders own shares in Phylogica and we see no evidence to suggest they are worried about the future. I like to dive deeper into how a company has performed in the past. You can access this interactive graph of past earnings, revenue and cash flow for free.

But note: Phylogica may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.